EANS-News: SYGNIS Pharma AG / SYGNIS announces nine months results of fiscal year 2011/2012

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

9-month report

Heidelberg (euro adhoc) - SYGNIS announces nine months results of
fiscal year 2011/2012

Heidelberg, February 14, 2012 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its financial
results for the third quarter and the first nine months of the
fiscal year 2011/2012 ended December 31, 2011.

Financials

• The net loss in the third quarter was EUR-18.4 million (EUR-3.7
million Q3 2010/2011). The net loss for the first nine months of the
fiscal year 2011/2012 amounted to EUR-21.7 million (EUR-9.0
million nine months 2010/2011).
• The increase of net loss is due to non-cash write-downs of the AX200
development project for the treatment of acute stroke and goodwill with a
total amount of EUR18.7 million. The reduction of deferred tax liabilities
led to a tax income of EUR2.0 million.
• Total operating expenses (without write-downs) for the first nine months
were significantly down at EUR6.0 million (EUR9.3 million nine
months 2010/2011). Financial result was EUR0.8 million (EUR0.0 million
nine months 2010/2011).
• Cash including marketable securities amounted to EUR5.6 million as of
December 31, 2011 (EUR9.0 million December 31, 2010).
• In mid August 2011 SYGNIS completed a capital increase. At the end of the
subscription period, 3,076,623 new shares have been subscribed and
correspondingly the share capital increased from EUR13,752,881 to
EUR16,829,504. As a result, the Company received gross proceeds of EUR6.2
million.

Operational summary

• Even after a thorough analysis of the AXIS 2 data, which have been first
published in mid December 2011, no hints for efficacy have been found with
regard to a clinical improvement of stroke patients treated with AX200
relative to placebo-treated patients. The study missed all of its
endpoints. As a result, the activities with regard to the clinical
development of AX200 for the treatment of stroke will be ceased.
• Based on its "proof of concept" studies and by using one of its
proprietary assays, SYGNIS completed a programme designed to identify
suitable compounds that could have an effect on KIBRA activity. The
results of this screening programme are currently under further
development in order to identify drug candidates which can be protected by
new intellectual property rights and optimized chemically as well as
pharmacologically. Furthermore, the patent situation for the KIBRA project
has also been improved. In September 2011 SYGNIS filed new patent
applications, which include new pharmacological pathways to KIBRA.

Outlook

Due to the write-downs of the AX200 development project and
Goodwill the net loss for the current 2011/2012 fiscal year is
expected to be significantly higher than originally planned. With
the current liquidity the Company is financed approximately
until the end of calendar year 2012.

Considering the termination of the clinical development of
AX200 for the treatment of acute stroke, the key operational focus
for the upcoming months is the protection as well as the sustainable
expansion of the remaining assets of the Company. Accordingly, the
Company actually evaluates potential M&A-options and financing
opportunities.

With regard to the KIBRA project the results of the
substance-screening will be further optimized. The identified drug
candidates should enable SYGNIS to

either enter into a research partnership or further develop the compounds with
its own resources.

|Key financial figures for the third quarter of fiscal year |
|2011/2012 ended December 31, 2011 and corresponding figures (IFRS) |
|Numbers in million euros |Q3 2011/2012 |Q3 2010/2011 |
|Revenues |0.1 |0.0 |
|Total expenses |1.7 |3.7 |
|EBIT |-1.6 |-3.7 |
|Net results for the period |-18.4 |-3.7 |
|Intangible assets |2.6 |21.7 |
|Liquidity at end of quarter |5.6 |9.0 |
|Equity |1.1 |21.2 |
|(equity ratio in %) |(9) |(59) |
|Long-term financial liabilities |8.0 |8.0 |
|Operating Cash Flow |-2.4 |-2.1 |

|Key figures for the first nine months of fiscal year 2011/12 ended |
|December 31, 2011 and comparables (IFRS) |
|Numbers in million euros |9 months 2011/12|9 months 2010/11|
|Revenues |0.3 |0.2 |
|Total expenses |6.0 |9.3 |
|EBIT |-5.7 |-9.1 |
|Net results for the period |-21.7 |-9.0 |
|Operating cash flow |-7.0 |-6.4 |

The report on the third quarter which ended on December 31, 2011 is available
at the SYGNIS webpage at www.sygnis.de.

About SYGNIS Pharma
SYGNIS Pharma AG (Heidelberg, Germany) is a specialty drug development company,
focusing on innovative treatments for underserved human diseases. In the field

of cognitive disorders, the company is exploring compounds targeting
the KIBRA pathway, a novel approach to treat different forms of
dementia. There is great medical demand for new treatments as there
are currently no or only inadequate options available. SYGNIS
Pharma AG is listed on the Prime Standard of the Frankfurt
Stock Exchange under the ticker: LIOK; and ISIN: DE000A1E9B74.

For further information please contact:

SYGNIS Pharma AG
Dr. Franz-Werner Haas
Senior Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English